A new treatment for sleeping sickness, a life-threatening tropical disease, has received a positive review by the European Medicines Agency, paving the way for its approval in sub-Saharan Africa where the illness is endemic. The medicine, Fexinidazole Winthrop (fexinidazole), was developed through a collaboration between Sanofi SA and the non-profit organisation, Drugs for Neglected Diseases initiative (DNDi).
The antibody-drug conjugate Adcetris (brentuximab vedotin) has received a new lymphoma indication from the US Food and Drug Administration under a procedure that allows the agency to study key clinical data for the compound prior to its formal regulatory application.
The US Food and Drug Administration is proposing a waiver to the legal requirement on pharma companies to obtain informed patient consent for certain low-risk clinical trials. The proposal would amend a provision of the 21st Century Cures Act to add an exception to the consent requirement.
The proposed rule, if finalized, would allow the institutional review board (IRB) responsible for the review and approval of clinical research to waive or alter certain elements of informed consent, or to waive the requirement entirely, under limited circumstances.
The European Medicines Agency has recommended the approval of Dengvaxia (dengue tetravalent vaccine) for the prevention of dengue, the most common mosquito-borne viral disease affecting people worldwide. The vaccine is for the prevention of dengue caused by the virus serotypes 1,2,3 and 4 in people between the ages of nine and 45 and who have already had a prior infection.
The European Medicines Agency has issued new guidance to industry on Brexit, warning that all products under review by the UK regulatory authority will need to be transferred to rapporteurs or co-rapporteurs from the other EU member states. The rapporteur is the leader of the scientific team that evaluates applications from companies for marketing authorisations. The activities of this team are supported by the EMA secretariat. Once outside the EU, the UK’s Medicines and Healthcare products Regulatory Agency will no longer be eligible to participate in these evaluations.
The US Food and Drug Administration approved Libtayo (cemiplimab-rwlc) on 28 September for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) who are not eligible for curative surgery or radiation. The approval is the FDA’s first authorisation of a drug specifically for an advanced form of this disease.
The US Food and Drug Administration has approved Lumoxiti (moxetumomab pasudotox-tdfk), a new drug developed by AstraZeneca Plc for the treatment of refractory hairy cell leukaemia (HCL), a rare, slow-growing cancer of the blood.
The US Food and Drug Administration has issued a ‘complete response letter’ to GlaxoSmithKline Plc rejecting the company’s application for a third indication for mepolizumab (Nucala). The application was to use the drug as an add-on treatment for patients with chronic obstructive pulmonary disease (COPD).
Announcing the rejection on 7 September, GSK said the FDA is requiring more data to support the proposed indication.
Two US institutions have taken steps to simplify the regulation of gene therapy, and bring the oversight of these technologies into the existing framework for monitoring experimental medicines. The shift in policy is described by Francis Collins, director of the National Institutes of Health, and Scott Gottlieb, commissioner of the Food and Drug Administration, in an article in the New England Journal of Medicine on 15 August 2018.
China-based Zhejiang Tianyu Pharmaceutical Co Ltd has had its regulatory clearance for the supply of the active ingredient valsartan to the European market suspended following an inspection showing the presence of N-nitrosodimethylamine (NDMA), a suspected carcinogen. NDMA is classified as a probable human cardinogen based on the results of laboratory tests.